What is it about?
Identification of chromosome abnormalities is continuously improving as technical advances in conventional and molecular cytogenetics improve the resolution and availability of cytogenetic information. Cancer treatment decisions are increasingly based on the unique genetic properties of each neoplasm. FISH, as a powerful approach to diagnosis, classification, and augury of malignant diseases can stratify cancers into clinically and biologically relevant subgroups, often irrespective of morphological classification systems.
Featured Image
Why is it important?
FISH technology is compatible not only with routine diagnostic pathology practice, but also with clinical investigations such as retrospective tissue analyses. FISH-detected chromosome alterations are easily correlated with biological and clinical endpoints.
Perspectives
The hypothesis that an abnormal chromosomal pattern is intimately associated with the malignant phenotype of a tumor has proven to be correct for many malignant disorders. Better knowledge of the molecular phenotypes of a disease will lead to more innovative and specific treatments. As more diagnostic and treatment decisions are based on results of FISH, demand for the technology will become more widespread. As the need for FISH increases, improved automation will lead to greater consistency and reproducibility of results. The emission stability and versatility of nanoparticle fluorochrome labels may, in the future, move these reagents from the research lab to the clinical diagnostic service.
Dr Shaobo Zhang
Indiana University School of Medicine
Read the Original
This page is a summary of: Fluorescencein situhybridization in surgical pathology: principles and applications, The Journal of Pathology Clinical Research, February 2017, Wiley,
DOI: 10.1002/cjp2.64.
You can read the full text:
Contributors
The following have contributed to this page
